Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001641172-25-002476 0001261725 XXXXXXXX LIVE 4 COMMON STOCK, $0.0001 PAR VALUE 09/17/2025 false 0001644488 819536103 SHARING SERVICES GLOBAL Corp 5200 TENNYSON PKWY #400 Plano TX 75024 Chan Heng Fai 011 65 6333 9181 9 Temasek Boulevard #16-04 Suntec Tower Two Singapore U0 038989 0001261725 N Heng Fai Ambrose Chan a OO N U0 40360.00 25933666.00 40360.00 25933666.00 25933666.00 N 99.3 IN Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. The figure set forth above includes (i) 86 shares held by Heng Fai Holdings Limited; (ii) 2,550,305 shares held by Alset Inc. (including debt of the Issuer which may be converted into 2,500,000 shares of the Issuer's common stock); (iii) debt and warrants of the Issuer held by HWH International Inc., which may be converted into 23,303,573 shares of the Issuer; (iv) 30,524 shares held by Alset International Limited; (v) 8,904 shares held by Global Biomedical Pte. Ltd.; and (vi) 39,650 shares held by Mr. Chan personally. Mr. Heng Fai Ambrose Chan is: (i) the sole director and sole shareholder of Heng Fai Holdings Limited; (ii) the Chief Executive Officer and Chairman of the Board of Directors of Alset Inc.; (iii) the Chairman of the Board of Directors of HWH International Inc.; (iv) the group Chief Executive Officer of Alset International Limited; and (v) Director of Global Biomedical Pte. Ltd. Accordingly, due to his interest in, and control over these entities, Mr. Chan indirectly holds beneficial interest in shares of the Issuer owned by such entities, and can exercise common control over the voting powers of these shares of the Issuer. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of September 19, 2025. Y Heng Fai Holdings Limited a OO N K3 0.00 86.00 0.00 86.00 86.00 N 0 CO Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. Mr. Heng Fai Ambrose Chan is the sole director and sole shareholder of Heng Fai Holdings Limited, accordingly, due to his interest in, and control over Heng Fai Holdings Limited, Mr. Chan indirectly holds beneficial interest in shares of the Issuer owned by Heng Fai Holdings Limited, and can exercise common control over the voting powers of these shares of the Issuer. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of September 19, 2025. 0001750106 N Alset Inc. a OO N TX 0.00 25893306.00 0.00 25893306.00 25893306.00 N 99.2 CO Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. Comprises (i) 2,550,305 shares held by Alset Inc. (including debt of the Issuer which may be converted into 2,500,000 shares of the Issuer's common stock); (iii) debt and warrants of the Issuer held by HWH International Inc., which may be converted into 23,303,573 shares of the Issuer; (iv) 30,524 shares held by Alset International Limited; and (v) 8,904 shares held by Global Biomedical Pte. Ltd. Alset Inc. has voting and dispositive control over HWH International Inc., Alset International Limited and Global Biomedical Pte. Ltd. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of September 19, 2025. 0001897245 N HWH International Inc. a OO N DE 0.00 23303573.00 0.00 23303573.00 23303573.00 N 98.7 CO Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. Comprises debt and warrants of the Issuer held by HWH International Inc. convertible into 23,303,573 shares of the Issuer's common stock. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of September 19, 2025. 0001660984 N Alset International Limited a OO N U0 0.00 39428.00 0.00 39428.00 39428.00 N 12.7 CO Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. Comprises (i) 30,524 shares held by Alset International Limited, and (ii) 8,904 shares held by Global Biomedical Pte. Ltd. Alset International Limited has voting and dispositive control over Global Biomedical Pte. Ltd. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of September 19, 2025. 0001823066 N Global Biomedical Pte. Ltd. a OO N U0 0.00 8904.00 0.00 8904.00 8904.00 N 2.8 CO Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of September 19, 2025. COMMON STOCK, $0.0001 PAR VALUE SHARING SERVICES GLOBAL Corp 5200 TENNYSON PKWY #400 Plano TX 75024 Heng Fai Ambrose Chan 9 Temasek Boulevard #16-04, Suntec Tower Two, Singapore 038989 Chief Executive Officer - Alset International Limited None. None. Singapore The information set forth in Item 4 hereof is incorporated by reference in its entirety into this Item 3. On June 27, 2025, the Issuer issued a convertible promissory note to HWH International Inc. ("HWH") in the amount of $60,000. This note is convertible into the Issuer's common stock at $0.006 per share at HWH's option until the maturity of the convertible note three (3) years from the date thereof. On September 17, 2025, the Issuer issued a convertible promissory note to HWH in the amount of $70,000. This note is convertible into the Issuer's common stock at $0.006 per share at HWH's option until the maturity of the convertible note three (3) years from the date thereof. Mr. Heng Fai Ambrose Chan ("Mr. Chan") serves on, and is the Chairman of, the Issuer's Board of Directors, Mr. Chan is also: (i) the sole Director and sole Shareholder of Heng Fai Holdings Limited; (ii) the Chief Executive Officer and Chairman of the Board of Directors of Alset Inc.; (iii) the Chairman of the Board of Directors of HWH International Inc.; (iv) the Group Chief Executive Officer of Alset International Limited; and (v) the Director of Global Biomedical Pte. Ltd. Accordingly, due to his interest in, and control over these entities, Mr. Chan indirectly holds beneficial interest in shares of the Issuer's common stock owned by such entities, and can exercise common control over the voting powers of these shares. The Reporting Persons, either directly or indirectly through Mr. Chan, may engage in discussions from time to time with the Issuer's Board of Directors, the Issuer's management or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing of the shares of Common Stock or other securities of the Issuer; (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional securities of the Issuer through open market transactions, privately negotiated transactions or other methods. Except as described in Item 6 and this Item 4 and any plans or proposals that may from time to time be discussed or considered by the directors of the Issuer, including Mr. Chan in his fiduciary capacity as a director of the Issuer, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the actions specified in in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments. The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 309,652 shares of Common Stock outstanding as of September 18, 2025, as reported by the Issuer to the Reporting Persons. The percentages of beneficial ownership were determined in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended. Information with respect to all transactions in the Shares beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Item 4 and incorporated herein by reference. The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 309,652 shares of Common Stock outstanding as of September 18, 2025, as reported by the Issuer to the Reporting Persons. The percentages of beneficial ownership were determined in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended. Information with respect to all transactions in the Shares beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Item 4 and incorporated herein by reference. There were no other transactions effected in the last 60 days by the Reporting Person except for the transactions which are the subject of this Schedule 13D. Not applicable. Not applicable. The information set forth in Item 4 hereof is incorporated by reference in its entirety into this Item 6. Other than the relationship as set out in Item 4 hereof, there are no other contracts, arrangements, understandings or relationships with respect to the Issuer's securities, among the Reporting Persons. Exhibit 99.1 - Joint Filing Agreement dated January 28, 2025 Heng Fai Ambrose Chan /s/ Heng Fai Ambrose Chan Heng Fai Ambrose Chan/An individual 09/19/2025 Heng Fai Holdings Limited /s/ Heng Fai Ambrose Chan Heng Fai Ambrose Chan, Director 09/19/2025 Alset Inc. /s/ Heng Fai Ambrose Chan Heng Fai Ambrose Chan/Chief Executive Officer 09/19/2025 HWH International Inc. /s/ Rongguo Wei Rongguo Wei/Chief Financial Officer 09/19/2025 Alset International Limited /s/ Heng Fai Ambrose Chan Heng Fai Ambrose Chan/Chief Executive Officer 09/19/2025 Global Biomedical Pte. Ltd. /s/ Heng Fai Ambrose Chan Heng Fai Ambrose Chan/Director 09/19/2025